懷俄明州夏延，2026 年 1 月 21 日（全球新聞稿）——CS Diagnostics Corp.（OTCQB：CSDX）今天詳細介紹了其 多渠道銷售策略、全球物流合作伙伴關係 和 可持續發展路線圖，以支持 MEDUSA SDP 的商業推廣。
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92/logo.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92/logo.png"/>
公司計劃通過多樣化的銷售模式分銷 MEDUSA SDP，以滿足機構和消費者的需求。
B2B 分銷渠道包括：
<ul>
<li>醫院和醫療機構</li>
<li>健身房和健康中心</li>
<li>學校和教育機構</li>
<li>企業和工業客户</li>
</ul>
B2C 渠道包括：
<ul>
<li>在 阿聯酋 和 德國 的實體零售店貨架上。</li>
<li>在線市場，如 亞馬遜、Noon 和領先的德國電子商務平台</li>
<li>通過官方 MEDUSA 電子商務網站 進行直接面向消費者的銷售</li>
</ul>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png"/>
為了支持高效的全球履行，DHL 已被選為大宗和機構貨物運輸的承運商，而 FedEx 將負責零售和麪向消費者的配送。
展望未來，公司預計將開始 生物可降解、可溶解的 MEDUSA SDP 濕巾系列 的監管審批流程，這代表了可持續衞生解決方案的突破性進展，並強化了 CSDX 的長期環境戰略。
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/22a15a74-b111-4b35-8fca-b3f8252f17c1/medusa-wipes.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/22a15a74-b111-4b35-8fca-b3f8252f17c1/medusa-wipes.png"/>
“CS Group 專注於有序執行、戰略合作伙伴關係和可擴展增長，” 管理層表示。“MEDUSA SDP 展示了我們如何將創新轉化為商業上可行、全球相關的產品，同時推動可持續發展。”
關於 CS Diagnostics Corp
CS Diagnostics Corp.（OTCQB：CSDX）是一家醫療技術公司，推動感染控制和腫瘤學的雙重重點平台，瞄準全球醫療保健市場的高優先級領域。公司的產品組合包括 MEDUSA，一個智能消毒劑和衞生解決方案平台，正在擴展到用於機構和消費者的濕巾和液體配方，以及 CS Protect-Hydrogel，一種在前列腺癌放療期間保護健康器官的組織間隔器。CSDX 正在通過關鍵的商業化里程碑，包括戰略製造合作伙伴關係、在海灣合作委員會和歐洲的多地區推出、多樣化的 B2B 和 B2C 分銷渠道、全球物流協議以及不斷增長的知識產權和監管路線圖。計劃推出生物可降解、可溶解的衞生產品並擴展國際市場。
前瞻性聲明
本公告包含與預期或預期未來事件和結果相關的前瞻性聲明，這些聲明具有前瞻性特徵，因此受到某些風險和不確定性的影響，例如一般經濟、市場和商業條件、合格員工的競爭、監管過程和行動、技術問題、新立法、由於潛在延誤或計劃變更而產生的不確定性、在新的政治管轄區工作所帶來的不確定性、勘探結果的不確定性、勘探權的時機和授予的不確定性、監管和其他第三方同意及批准的時機和授予的不確定性、公司或任何第三方執行和實施未來計劃的能力的不確定性，以及意外事件的發生。
實際結果可能因眾多已知和未知的風險、不確定性和其他因素而與此處提供的信息有所不同。
欲瞭解更多信息，請訪問 https://medusa-sdp.com/en/
或聯繫
Mohammad Essayed
電子郵件：info@csdcorp.us
隨本公告附帶的照片可在以下網址獲取：
https://www.globenewswire.com/NewsRoom/AttachmentNg/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c
https://www.globenewswire.com/NewsRoom/AttachmentNg/22a15a74-b111-4b35-8fca-b3f8252f17c1
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9UYzRNaU0zTXpjek1EazBJelV3TURFMU56VXlNZz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9UYzRNaU0zTXpjek1EazBJelV3TURFMU56VXlNZz09"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGFlZjc2YWUtMDM5Ni00ZTlhLWFlZjAtZDIyZmJhZDQ0NzFjLTUwMDE1NzUyMi0yMDI2LTAxLTIxLWVu/tiny/CS-Diagnostics-Corp-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGFlZjc2YWUtMDM5Ni00ZTlhLWFlZjAtZDIyZmJhZDQ0NzFjLTUwMDE1NzUyMi0yMDI2LTAxLTIxLWVu/tiny/CS-Diagnostics-Corp-.png"/>

CS Diagnostics Corp.（OTCQB：CSDX）宣佈了一項針對其 MEDUSA SDP 產品的多渠道銷售策略，目標是機構市場和消費者市場。該公司將與 DHL 和 FedEx 合作，利用其全球物流網絡。此外，CSDX 計劃推出可生物降解的濕巾，作為其可持續發展路線圖的一部分。管理層強調通過嚴格執行和戰略合作伙伴關係來推動醫療保健領域的增長和創新

CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy, global logistics partnerships, and sustainability roadmap supporting the commercial rollout of MEDUSA SDP.
<div class="lb-trans">懷俄明州夏延，2026 年 1 月 21 日（全球新聞稿）——CS Diagnostics Corp.（OTCQB：CSDX）今天詳細介紹了其 多渠道銷售策略、全球物流合作伙伴關係 和 可持續發展路線圖，以支持 MEDUSA SDP 的商業推廣。
</div><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92/logo.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92/logo.png"/>
The Company plans to distribute MEDUSA SDP through a diversified sales model designed to serve both institutional and consumer demand.
<div class="lb-trans">公司計劃通過多樣化的銷售模式分銷 MEDUSA SDP，以滿足機構和消費者的需求。
</div>B2B distribution channels include:
<div class="lb-trans">B2B 分銷渠道包括：
</div><ul>
<li>Hospitals and healthcare facilities</li>
<li>Gyms and wellness centers</li>
<li>Schools and educational institutions</li>
<li>Corporate and industrial clients</li>
</ul>
<div class="lb-trans"><ul>
<li>醫院和醫療機構</li>
<li>健身房和健康中心</li>
<li>學校和教育機構</li>
<li>企業和工業客户</li>
</ul>
</div>B2C channels include:
<div class="lb-trans">B2C 渠道包括：
</div><ul>
<li>Physical retail Stores shelves, in UAE and Germany.</li>
<li>Online marketplaces such as Amazon, Noon, and leading German e-commerce platforms</li>
<li>Direct-to-consumer sales via the official MEDUSA e-commerce website</li>
</ul>
<div class="lb-trans"><ul>
<li>在 阿聯酋 和 德國 的實體零售店貨架上。</li>
<li>在線市場，如 亞馬遜、Noon 和領先的德國電子商務平台</li>
<li>通過官方 MEDUSA 電子商務網站 進行直接面向消費者的銷售</li>
</ul>
</div><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png"/>
<div class="lb-trans"><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c/medusa-drink.png"/>
</div>To support efficient global fulfillment, DHL has been selected for bulk and institutional shipments, while FedEx will manage retail and consumer-focused deliveries.
<div class="lb-trans">為了支持高效的全球履行，DHL 已被選為大宗和機構貨物運輸的承運商，而 FedEx 將負責零售和麪向消費者的配送。
</div>Looking ahead, the Company expects to begin regulatory approval processes for a bio-degradable, dissolving MEDUSA SDP wet wipes line, representing a breakthrough advancement in sustainable hygiene solutions and reinforcing CSDX’s long-term environmental strategy.
<div class="lb-trans">展望未來，公司預計將開始 生物可降解、可溶解的 MEDUSA SDP 濕巾系列 的監管審批流程，這代表了可持續衞生解決方案的突破性進展，並強化了 CSDX 的長期環境戰略。
</div><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/22a15a74-b111-4b35-8fca-b3f8252f17c1/medusa-wipes.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/22a15a74-b111-4b35-8fca-b3f8252f17c1/medusa-wipes.png"/>
“CS Group is focused on disciplined execution, strategic partnerships, and scalable growth,” Management stated. “MEDUSA SDP demonstrates how we translate innovation into commercially viable, globally relevant products while advancing sustainability.”
<div class="lb-trans">“CS Group 專注於有序執行、戰略合作伙伴關係和可擴展增長，” 管理層表示。“MEDUSA SDP 展示了我們如何將創新轉化為商業上可行、全球相關的產品，同時推動可持續發展。”
</div>About CS Diagnostics Corp
<div class="lb-trans">關於 CS Diagnostics Corp
</div>CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company’s portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, a multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap. With plans to introduce biodegradable, dissolving hygiene products and expand internationally.
<div class="lb-trans">CS Diagnostics Corp.（OTCQB：CSDX）是一家醫療技術公司，推動感染控制和腫瘤學的雙重重點平台，瞄準全球醫療保健市場的高優先級領域。公司的產品組合包括 MEDUSA，一個智能消毒劑和衞生解決方案平台，正在擴展到用於機構和消費者的濕巾和液體配方，以及 CS Protect-Hydrogel，一種在前列腺癌放療期間保護健康器官的組織間隔器。CSDX 正在通過關鍵的商業化里程碑，包括戰略製造合作伙伴關係、在海灣合作委員會和歐洲的多地區推出、多樣化的 B2B 和 B2C 分銷渠道、全球物流協議以及不斷增長的知識產權和監管路線圖。計劃推出生物可降解、可溶解的衞生產品並擴展國際市場。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性聲明
</div>This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
<div class="lb-trans">本公告包含與預期或預期未來事件和結果相關的前瞻性聲明，這些聲明具有前瞻性特徵，因此受到某些風險和不確定性的影響，例如一般經濟、市場和商業條件、合格員工的競爭、監管過程和行動、技術問題、新立法、由於潛在延誤或計劃變更而產生的不確定性、在新的政治管轄區工作所帶來的不確定性、勘探結果的不確定性、勘探權的時機和授予的不確定性、監管和其他第三方同意及批准的時機和授予的不確定性、公司或任何第三方執行和實施未來計劃的能力的不確定性，以及意外事件的發生。
</div>Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.
<div class="lb-trans">實際結果可能因眾多已知和未知的風險、不確定性和其他因素而與此處提供的信息有所不同。
</div>For further information, please visit https://medusa-sdp.com/en/
<div class="lb-trans">欲瞭解更多信息，請訪問 https://medusa-sdp.com/en/
</div>or contact
<div class="lb-trans">或聯繫
</div>Mohammad Essayed
<div class="lb-trans">Mohammad Essayed
</div>Email: info@csdcorp.us
<div class="lb-trans">電子郵件：info@csdcorp.us
</div>Photos accompanying this announcement are available at:
<div class="lb-trans">隨本公告附帶的照片可在以下網址獲取：
</div>https://www.globenewswire.com/NewsRoom/AttachmentNg/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92
<div class="lb-trans">https://www.globenewswire.com/NewsRoom/AttachmentNg/41a98fdf-ea7e-43e7-bc45-d5ba415c9a92
</div>https://www.globenewswire.com/NewsRoom/AttachmentNg/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c
<div class="lb-trans">https://www.globenewswire.com/NewsRoom/AttachmentNg/dd6a88b8-aad6-4327-b9bf-47c89ed48a1c
</div>https://www.globenewswire.com/NewsRoom/AttachmentNg/22a15a74-b111-4b35-8fca-b3f8252f17c1
<div class="lb-trans">https://www.globenewswire.com/NewsRoom/AttachmentNg/22a15a74-b111-4b35-8fca-b3f8252f17c1
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9UYzRNaU0zTXpjek1EazBJelV3TURFMU56VXlNZz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyOTc4MiM3MzczMDk0IzUwMDE1NzUyMg=="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGFlZjc2YWUtMDM5Ni00ZTlhLWFlZjAtZDIyZmJhZDQ0NzFjLTUwMDE1NzUyMi0yMDI2LTAxLTIxLWVu/tiny/CS-Diagnostics-Corp-.png" alt="" original-src="https://ml.globenewswire.com/media/OGFlZjc2YWUtMDM5Ni00ZTlhLWFlZjAtZDIyZmJhZDQ0NzFjLTUwMDE1NzUyMi0yMDI2LTAxLTIxLWVu/tiny/CS-Diagnostics-Corp-.png"/>

CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP | CSDX Stock News

StockTitan

Cardio Diagnostics

基因改革 ETF - ARK

醫療業 ETF - SPDR

美國醫療保健供應商 ETF - iShares

標普健康醫療設備 ETF - SPDR

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

基因免疫&健康關懷 ETF - iShares

CARDIO DIAGNOSTICS HOLDINGS INC C/WTS (10/25/2027) TO PUR COM

美國醫藥設備 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

CS Group (OTCQB: CSDX) 宣佈了關於 MEDUSA SDP 的多渠道銷售模式、全球物流合作伙伴以及可持續創新路線圖 | CSDX 股票新聞